Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
-
Support Care Cancer · May 1994
Prevention of aspiration pneumonia during long-term feeding by percutaneous endoscopic gastrostomy: might cisapride play any role? An open pilot study.
The risk of aspiration during tube feedings has been reduced but not abolished by percutaneous endoscopic gastrostomy (PEG). This open study was planned to evaluate whether cisapride may play some role in preventing aspiration in long-term enteral feeding via PEG. A group of 29 patients, unable to swallow because of head and neck cancer (14 cases) or neurological disorders (15 cases) entered the study; 7 neurological patients, fed via nasogastric tube before PEG placement, had suffered from aspiration pneumonia during nasogastric feeding. ⋯ No episode of probable/possible aspiration pneumonia was observed during the follow-up. Two neurological patients with involuntary movements had rupture of the feeding tube, which was replaced without complications. These results support the hypothesis that cisapride might play some role in the prevention of aspiration in patients fed via PEG, and justify the planning of some controlled, double-blind trials to verify such a hypothesis.
-
Support Care Cancer · May 1994
Case ReportsClinical application of nebulized opioids for treatment of dyspnoea in patients with malignant disease.
This article describes our experience in the clinical use of nebulized opioids for the management of dyspnoea in patients with terminal cancer by reviewing three specific patient case studies in which this treatment was found to be both safe and effective in controlling breathlessness. The patients were treated with morphine, hydromorphone or anileridine in various doses according to their prior use of opioids. Additional formal studies are being initiated at this Centre.
-
Support Care Cancer · Mar 1994
Clinical TrialTransdermal fentanyl in uncontrolled cancer pain: titration on a day-to-day basis as a procedure for safe and effective dose finding--a pilot study in 20 patients.
All communications on the use of transdermal fentanyl as well as the recommendations of the manufacturer include the direction that patients should be titrated with a short-acting narcotic to control their cancer pain before they are converted to a fentanyl transdermal therapeutic system (TTS). We investigated the possibility of avoiding this titration phase by immediate fentanyl TTS therapy in patients with uncontrolled cancer pain. Dose finding was performed by direct titration of fentanyl TTS according to clinical necessity on a day-to-day basis. ⋯ There were statistically significant lower VAS values at all follow-up times compared to pretreatment values (e.g. pretreatment to day 1: P = 0.019; pretreatment to day 28: P = 0.002; Wilcoxon sign-rank test). The mean fentanyl TTS doses were 70 micrograms/h (week 1), 98 micrograms/h (week 2), 107 micrograms/h (week 3) and 116 micrograms/h (week 4). The differences of mean fentanyl TTS does were significantly different between days 1 and 7 (P < 0.001) and between days 8 and 14 (P = 0.006), but not between days 15 and 21 and days 22 and 28.(ABSTRACT TRUNCATED AT 250 WORDS)
-
Support Care Cancer · Jan 1994
Editorial Case ReportsPalliative care in high-tech medicine: defining the point of no return.
-
Support Care Cancer · Nov 1993
Randomized Controlled Trial Clinical TrialRespiratory distress syndrome in patients with advanced cancer treated with pentoxifylline: a randomized study.
The inappropriate endogenous secretion of tumour necrosis factor (TNF) could play a role in the pathogenesis of acute respiratory distress syndrome (ARDS), one of the most frequent causes of death in cancer patients. Because of its capacity to inhibit TNF secretion in vitro, pentoxifylline (PTX) could be extremely useful in ARDS therapy. In this study 30 advanced cancer patients with ARDS were randomized to receive either the conventional care or conventional care plus PTX (100 mg i.v. twice a day for 7 days followed by an oral administration of 400 mg three times a day) to evaluate the efficacy of PTX in reducing TNF serum levels and in improving the symptoms of this syndrome. ⋯ TNF mean levels significantly decrease in the PTX-treated group. These data confirm in vivo the capacity of PTX to inhibit TNF secretion in patients with ARDS. Moreover PTX therapy may improve the symptoms related to ARDS without particular toxic effects.